Market open
Opus Genetics/$IRD
Opus Genetics shares are trading higher after announcing positive one-month clinical data from a pediatric patient in a Phase 1/2 trial of their gene therapy for inherited retinal diseases.
4 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Ticker
$IRD
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
14
Website
Opus Genetics Metrics
BasicAdvanced
$38M
-
-$2.15
0.27
-
Price and volume
Market cap
$38M
Beta
0.27
52-week high
$2.18
52-week low
$0.80
Average daily volume
243K
Financial strength
Current ratio
3.241
Quick ratio
3.196
Management effectiveness
Return on assets (TTM)
-46.90%
Return on equity (TTM)
-152.46%
Valuation
Price to revenue (TTM)
2.056
Price to book
3.97
Price to tangible book (TTM)
3.97
Growth
Revenue change (TTM)
-42.30%
Earnings per share change (TTM)
365.59%
3-year revenue growth (CAGR)
165.25%
3-year earnings per share growth (CAGR)
-17.39%
What the Analysts think about Opus Genetics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Opus Genetics stock.
Opus Genetics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Opus Genetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Opus Genetics News
AllArticlesVideos
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
GlobeNewsWire·7 hours ago
Opus Genetics to Participate in Upcoming Investor Conference in April
GlobeNewsWire·6 days ago
Opus Genetics Announces Financial Results for Full Year 2024
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Opus Genetics stock?
Opus Genetics (IRD) has a market cap of $38M as of April 08, 2025.
What is the P/E ratio for Opus Genetics stock?
The price to earnings (P/E) ratio for Opus Genetics (IRD) stock is 0 as of April 08, 2025.
Does Opus Genetics stock pay dividends?
No, Opus Genetics (IRD) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Opus Genetics dividend payment date?
Opus Genetics (IRD) stock does not pay dividends to its shareholders.
What is the beta indicator for Opus Genetics?
Opus Genetics (IRD) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.